FDA 483 OBSERVATION · #2 OF 1,923 MOST-CITED
Lack of or inadequate procedures
FDA cited this observation 2,370 times across 1,998 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A procedure the regulation requires either did not exist in writing, or existed but did not actually control the activity it governs — it was missing key steps, acceptance criteria, or the scope needed to prevent the failure it is supposed to prevent.
Why FDA writes it — Written, adequate procedures are the backbone of every FDA quality system. When FDA finds a problem, the first question is whether a procedure existed to prevent it; an absent or hollow procedure is both a finding in itself and the reason downstream failures were possible.
- Map every activity the regulation requires you to control to a specific, approved procedure — and confirm each procedure actually specifies who does what, when, to what acceptance criteria.
- Write procedures against the failure mode, not the audit: a procedure that recites the regulation but omits the decision points operators actually face is “inadequate,” even if it exists.
- Keep procedures current with practice — a document describing a process that has since changed is treated as no procedure at all.
- Train to the procedure and record that training, so “adequate” is demonstrable and not just asserted.
- Procedures written to pass an audit rather than to run the process — generic, uncontroversial, and silent on the hard judgment calls.
- Drift: the process evolved on the floor but the controlled document was never revised to match.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.2× the rate of the average FDA-cited firm (9.0% vs 7.8%), across 1,998 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for corrective and preventive action have not been adequately established.
Procedures for corrective and preventive action have not been adequately established.
Procedures for corrective and preventive action have not been adequately established.
Procedures for corrective and preventive action have not been established.
Procedures for corrective and preventive action have not been established.
Procedures for corrective and preventive action have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →